We have previously reported a gene signature (PIK3CA-GS) derived from patients with estrogen receptor (ER)-positive breast cancer with PIK3CA kinase domain mutations which was able to predict PIK3CA mutation status (genotype) in independent datasets and was also associated with better outcomes in tamoxifen-treated ER-positive breast cancers [7]. The gene discussed is ESR1; the disease is breast cancer.